Effects of repeated systemic administration of 1-methyl-4- phenyl1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1β and nerve growth factor in the striatum

Neuroscience Letters

Volumn 250, Issue 1, 1998, Pages 25-28

  Mogi, Makio ^a   Togari, Akifumi ^a   Ogawa, Matsuo ^b   Ikeguchi, Kunihiko ^b   Shizuma, Nami ^b   Fan, Dong shen ^b   Nakano, Imaharu ^b   Nagatsu, Toshiharu ^c  

^a AICHI GAKUIN UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Brain; Interleukin 1 ; Mice; Nerve growth factor; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; INTERLEUKIN 1BETA; NERVE GROWTH FACTOR; NEUROTROPHIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; FRONTAL CORTEX; MOUSE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PUTAMEN;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; CORPUS STRIATUM; DOPAMINE AGENTS; DRUG ADMINISTRATION SCHEDULE; INJECTIONS, INTRAVENTRICULAR; INTERLEUKIN-1; MICE; MICE, INBRED C57BL; NERVE GROWTH FACTORS;

EID: 0032569084     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00427-3     Document Type: Article

References (33)

1. Allen S.J., MacGowan S.H., Treanor J.J., Feeney R., Wilcock G.K., Dawbarn D. Normal β-NGF content in Alzheimer's disease cerebral cortex and hippocampus. Neurosci. Lett. 131:1991;135-139.
2. Boka G., Anglada P., Wallach D., Javoy-Agid F., Agid Y., Hirsch E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172:1994;151-154.
3. Bolanos J.P., Almeida A., Stewart V., Peuchen S., Land J.M., Clark J.B., Heales S.J. Nitric oxide-mediated mitochondrial damage in the brain: mechanisms and implications for neurodegenerative diseases. J. Neurochem. 68:1997;2227-2240.
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
5. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., Riederer P. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202:1995;17-20.
6. Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32:1992;804-812.
7. Fukuda T., Watabe K., Tanaka J. Effects of bromocriptine and/or L-DOPA on neurons in substantia nigra of MPTP-treated C57BL/6 mice. Brain Res. 728:1996;274-276.
8. Gerlach M., Ben-Shachar D., Riederer P., Youdim M.B.H. Altered brain metabolism of iron as a cause of neurodegenerative diseases. J. Neurochem. 63:1994;793-807.
9. Hefti F. Neurotrophic factor therapy for nervous system degenerative diseases. J. Neurobiol. 25:1994;1418-1435.
10. Jenner P. Oxidative damage in neurodegenerative disease. Lancet. 344:1994;796-798.
11. Kuhn W., Muller Th. Neuroimmune mechanisms in Parkinson's disease. J. Neural Transm. 46:1995;229-233.
12. Lindholm D., Heumann R., Meyer M., Thoenen H. Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve. Nature. 330:1987;658-659.
13. Lippa C.F., Smith T.W., Flanders K.C. Transforming growth factor-beta: neuronal and glial expression in CNS degenerative diseases. Neurodegeneration. 4:1995;425-432.
14. Marshall K.-A., Daniel S.E., Cairns N., Jenner P., Halliwell B. Upregulation of the anti-apoptotic protein bcl-2 may be an early event in neurodegeneration: studies on Parkinson's and incidental Lewy body disease. Biochem. Biophys. Res. Commun. 240:1997;84-87.
15. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Rev. 21:1995;195-218.
16. Mochizuki H., Goto K., Mori H., Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J. Neurol. Sci. 137:1996;120-123.
17. Mogi M., Harada M., Kondo T., Riederer P., Nagatsu T. Brain β2-microglobulin levels are elevated in the striatum in Parkinson's disease. J. Neural Transm. (P.-D. Sect.). 9:1995;87-92.
18. Mogi M., Harada M., Kondo T., Riederer P., Nagatsu T. Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. J. Neural Transm. 103:1996;1077-1081.
19. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165:1994;208-210.
20. Mogi M., Harada M., Kondo T., Narabayashi H., Riederer P., Nagatsu T. Transforming growth factor-β 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci. Lett. 193:1995;129-132.
21. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., Nagatsu T. Interleukin (IL)-1β, IL-2, IL-4, IL-6, and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 211:1996;13-16.
22. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180:1994;147-150.
23. Mogi M., Harada M., Kondo T., Mizuno Y., Narabayashi H., Riederer P., Nagatsu T. bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci. Lett. 215:1996;137-139.
24. Mogi M., Harada M., Kondo T., Mizuno Y., Narabayashi H., Riederer P., Nagatsu T. The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci. Lett. 220:1996;195-198.
25. Nagatsu T. Isoquinoline neurotoxins in the brain and Parkinson's disease. Neurosci Res. 29:1997;99-111.
26. Scott S.A., Mufson E.J., Weingartner J.A., Skau K.A., Crutcher K.A. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J. Neurosci. 15:1995;6213-6221.
27. Stern G. Parkinson's disease: the apoptosis hypothesis. Adv. Neurol. 69:1996;101-107.
28. Snyder S.H. Parkinson's disease. Fresh factors to consider. Nature. 350:1991;195-196.
29. Vawter M.P., Dillon-Carter O., Tourtellotte W.W., Carvey P., Freed W.J. TGFβ1 and TGFβ2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Exp. Neurol. 142:1996;313-322.
30. Walkinshaw G., Waters C.M. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. J. Clin. Invest. 95:1995;2458-2464.
31. Weiss R. Promising protein for Parkinson's. Science. 260:1993;1072-1073.
32. Wood J.A., Wood P.L., Ryan R., Graff-Radford N.R., Pilapil C., Robitaille Y., Quirion R. Cytokine induces in Alzheimer's temporal cortex: no changes in mature IL-1β or IL-1RA but increases in the associated acute phase proteins IL-6, α2-macroglobulin and C-reactive protein. Brain Res. 629:1993;245-252.
33. Ziv I., Zilkha-Falb R., Offen D., Shirvan A., Barzilai A., Melamed E. Levodopa induces apoptosis in cultured neuronal cells, a possible accelerator of nigrostriatal degeneration of Parkinson's disease? Mov. Disord. 12:1997;17-23.